End-Stage Renal Disease
Conditions
Keywords
Peritoneal dialysis, L-carnitine
Brief summary
The development of glucose-sparing strategies able to provide an efficacious ultrafiltration profile represents one of the modern goals of peritoneal dialysis therapy. The study hypothesis is to evaluate the possibility to formulate peritoneal dialysis solutions containing L-carnitine as an osmotic agent to partially replace glucose.
Interventions
DRUGL-carnitine
Instillation of glucose-based (1.5% weight/volume) peritoneal dialysis solution containing L-carnitine (0.25% weight/volume) for the nocturnal exchange. Patients were treated with the experimental peritoneal dialysis solution for 5 days.
Sponsors
Iperboreal Pharma Srl
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥18 years * Have a diagnosis of End Stage Renal Disease and have been on Continuous Ambulatory Peritoneal Dialysis for at least 3 months * Be in a stable clinical condition during the four weeks immediately prior to Screening Period as demonstrated by medical history, physical examination and laboratory testing * Have a blood hemoglobin concentration above 8,5 g/100ml (data will be verified with Investigators) * Have not experienced peritonitis episodes in the last 3 months * Be treated with 3 diurnal exchange bag solutions (1.5% or 2.5% glucose) and one nocturnal exchange bag solution (2.5% glucose) * Have Kt/V urea measurement \> 1.7 per week in a previous test performed within 6 months that should be confirmed at Baseline Visit * Have a minimum weekly creatinine clearance of 45 litres in a previous test performed within 6 months that should be confirmed at Baseline Visit * Have a D/P Creatinine ratio at Peritoneal Equilibration Test between 0.50 and 0.81 in a previous test performed within 6 months that should be confirmed at Baseline Visit * Have a D/P Glucose ratio at Peritoneal Equilibration Test between 0.26 and 0.49 in a previous test performed within 6 months that should be confirmed at Baseline Visit * Be treated by the participating clinical Investigator for a period of at least three months * Have understood and signed the Informed Consent Form.
Exclusion criteria
* Have a history of drug or alcohol abuse in the six months prior to entering the protocol * Be in treatment with androgens * Have Diabetes Mellitus (as defined by the American Diabetes Society, objectively documented by a fasting plasma glucose and HbA1c determinations) * Have clinically significant abnormal liver function test (SGOT, SGPT, and gamma-GT \> 2 times the upper normal limit) * Have acute infectious conditions (i.e.: pulmonary infection, acute hepatitis, high or low urinary tract infections, renal parenchymal infection, pericarditis, etc) * Have a history of congestive heart failure and clinically significant arrhythmia * Have an history of epilepsy or any central nervous system disease * Have malignancy within the past 5 years, including lymphoproliferative disorders * Have any medical condition that, in the judgment of the Investigator, would jeopardize the patient's safety following exposure to study drug, particularly if patient's life expectancy is less than 1 year * Have a history of L-Carnitine therapy or use in the month prior to entering the protocol * Have used any investigational drug in the 3 months prior to entering the protocol * Pregnant, lactating, fertility age without protection against pregnancy by adequate contraceptive means
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Long Dwell Ultrafiltration | day 5 | The amount of fluid recovered from the peritoneum at the end of the nocturnal exchange (long dwell) with a peritoneal dialysis solution. |
Countries
Italy
Participant flow
Recruitment details
From June, 2004, to November, 2004. Medical Clinic
Pre-assignment details
One-week run-in
Participants by arm
| Arm | Count |
|---|---|
| Peritoneal Dialysis Solution The enrolled patients were using for the long dwell (nocturnal) exchange a glucose-based (2.5% w/v) peritoneal dialysis solution. | 4 |
| Total | 4 |
Baseline characteristics
| Characteristic | Peritoneal Dialysis Solution |
|---|---|
| Age Continuous | 61.6 years STANDARD_DEVIATION 11.9 |
| Region of Enrollment Italy | 4 participants |
| Sex: Female, Male Female | 1 Participants |
| Sex: Female, Male Male | 3 Participants |
| Ultrafiltration | 1987 milliliters STANDARD_DEVIATION 192 |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 0 / 4 |
| serious Total, serious adverse events | 0 / 4 |
Outcome results
Primary
Long Dwell Ultrafiltration
The amount of fluid recovered from the peritoneum at the end of the nocturnal exchange (long dwell) with a peritoneal dialysis solution.
Time frame: day 5
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Peritoneal Dialysis Solution | Long Dwell Ultrafiltration | 2167 milliliters | Standard Deviation 203 |